Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li>Concord Biotech is expected to announce its share allotment status today, August 11.</li><li>The shares of Concord Biotech were subscribed almost 25 times.</li><li>The shares are expected to be listed on the stock exchanges on August 18.</li></ul> Ahmedabad-based Concord Biotech, a biotech company, is expected to announce the allotment status of its initial public offering (IPO) today, that is August 11. The <keyword id="14731431" type="General" weightage="20" keywordseo="concord-biotech-ipo" source="Orion">Concord Biotech IPO</keyword> opened on August 4 and closed on August 8. The price band for the IPO was ₹705 to ₹741 per share. <cmsannotation type="cmsannotation" annotationid="Decent subscription" comment="subhead" text="Decent subscription">Decent subscription</cmsannotation> On the last day, the Concord Biotech IPO was subscribed 24.87 times, receiving bids for 36.42 crore equity shares against 1.46 crore shares on offer. While the qualified institutional buyer portion was subscribed 67.76 times, the non-institutional investors portion was subscribed 16.99 times. The retail portion also witnessed decent participation and was subscribed 3.78 times. The employee portion was subscribed 24.48 times. <cmsannotation type="cmsannotation" annotationid="Grey market premium" comment="subhead" text="Grey market premium">Grey market premium</cmsannotation> The shares of Concord Biotech are currently commanding a grey market premium (GMP) of ₹160 per share. GMP is the premium at which IPO shares are traded in an unofficial market before they are listed on the stock exchanges. <cmsannotation type="cmsannotation" annotationid="Here’s how to check the IPO’s allotment status" comment="subhead" text="Here’s how to check the IPO’s allotment status">Here’s how to check the IPO’s allotment status</cmsannotation> You can check the allotment status on the registrar’s website. <ul><li>To check the <keyword id="18352900" type="General" weightage="20" keywordseo="concord-biotech-ipo-allotment-status" source="Orion">Concord Biotech IPO allotment status</keyword>, visit the registrar’s website<a href="https://linkintime.co.in/IPO/public-issues.html"> here</a>.</li><li>Click on ‘Select Company’ and then select ‘Concord Biotech’.</li><li>Now, enter your PAN, application number, DP / Client ID or Account number / IFSC.</li><li>Now, enter the captcha.</li><li>Click on submit.</li></ul>You will be able to see your application status. It will display the number of shares that you have applied for and the number of shares that have been allotted to you. You can also check the <keyword id="18352899" type="General" weightage="100" keywordseo="concord-biotech-ipo-allotment" source="Orion">Concord Biotech IPO allotment</keyword> status on the BSE and NSE websites. To check the allotment status on BSE or NSE website: <ul><li>Go to the BSE<a href="https://www.bseindia.com/investors/appli_check.aspx"> website</a>.</li><li>On the website, click on 'Equity' and then select ‘Concord Biotech’ from the dropdown menu.</li><li>Now, enter your application number and PAN.</li><li>Click on 'Search'.</li></ul>You will be able to see the number of shares allotted to you. You can click<a href="https://www.nseindia.com/products-services/initial-public-offerings-bid-verification"> here</a> and log in to check your allotment status on NSE. <cmsannotation type="cmsannotation" annotationid="Concord Biotech IPO listing date" comment="subhead" text="Concord Biotech IPO listing date">Concord Biotech IPO listing date</cmsannotation> The shares of Concord Biotech will be listed on the stock exchanges on August 18. SEE ALSO: <a href="https://www.businessinsider.in/finance/news/cash-card-or-talk-rbi-bats-for-conversational-upi-increased-offline-payments/articleshow/102599474.cms">UPI joins the AI bandwagon, offline payments get a push</a> <a href="https://www.businessinsider.in/india/webstories/children-below-the-age-of-18-may-soon-have-to-get-parental-consent-to-use-social-media/slidelist/102601878.cms">Children below the age of 18 may soon have to get parental consent to use social media</a> <a href="https://www.businessinsider.in/tech/news/hp-omen-17-gaming-laptop-review-price-performance-and-design/articleshow/102570650.cms">HP OMEN 17 review: A powerful but heavy gaming laptop with a large display</a>

Concord Biotech IPO allotment – how to check allotment, GMP, listing date and more

<ul><li><keyword id="1979075" type="General" weightage="20" keywordseo="Indegene" source="Orion">Indegene</keyword> Limited is expected to announce its share allotment status on Thursday, May 9.</li><li>The shares of Indegene were subscribed 69.63 times.</li><li>The shares are expected to be listed on the stock exchanges on May 13.</li></ul>Bengaluru-based Indegene Limited, which provides services to biopharmaceutical, emerging biotech and medical device companies, is expected to announce the allotment status of its initial public offering (IPO) on Thursday, May 9. The <keyword id="15795988" type="General" weightage="20" keywordseo="Indegene-IPO" source="Orion">Indegene IPO</keyword> opened on May 6 and closed on May 8. The price band for the IPO was ₹430 to ₹452 per share. <cmsannotation type="cmsannotation" annotationid="Indegene IPO subscription" comment="subhead" text="Indegene IPO subscription">Indegene IPO subscription</cmsannotation> On its last day, the Juniper Hotels IPO was subscribed 69.63 times, receiving bids for 200.99 crore equity shares against 2.89 crore shares on offer. While the qualified institutional buyer (QIB) portion was subscribed 197.55 times, the non-institutional investors portion was subscribed 54.63 times. The retail portion witnessed decent participation and was subscribed 7.58 times. The employee portion was subscribed 6.2 times. <cmsannotation type="cmsannotation" annotationid="Indegene IPO Grey market premium" comment="subhead" text="Indegene IPO Grey market premium">Indegene IPO Grey market premium</cmsannotation> The shares of Indegene are currently commanding a grey market premium (GMP) of ₹260 per share. GMP is the premium at which IPO shares are traded in an unofficial market before they are listed on the stock exchanges. <cmsannotation type="cmsannotation" annotationid="Here’s how to check the Indegene IPO’s allotment status" comment="subhead" text="Here’s how to check the Indegene IPO’s allotment status">Here’s how to check the Indegene IPO’s allotment status</cmsannotation> You can check the allotment status on the registrar’s website. <ul><li>To check the <keyword id="21559171" type="General" weightage="100" keywordseo="Indegene-IPO-allotment" source="Orion">Indegene IPO allotment</keyword> status, visit the registrar’s website<a href="https://linkintime.co.in/initial_offer/public-issues.html"> here</a>.</li><li>Click on ‘Select Company’ and then select ‘Indegene’.</li><li>Now, enter your PAN, application number, DP / Client ID or Account number / IFSC.</li><li>Click on submit.</li></ul>You will be able to see your application status. It will display the number of shares that you have applied for and the number of shares that have been allotted to you. You can also check the Indegene IPO allotment status on the BSE and NSE websites. To check the allotment status on the BSE or NSE website: <ul><li>Go to the BSE<a href="https://www.bseindia.com/investors/appli_check.aspx"> website</a>.</li><li>On the website, click on 'Equity' and then select ‘Indegene’ from the dropdown menu.</li><li>Now, enter your application number and PAN.</li><li>Click on 'Search'.</li></ul>You will be able to see the number of shares allotted to you. You can click<a href="https://www.nseindia.com/products-services/initial-public-offerings-bid-verification"> here</a> and log in to check your allotment status on NSE. <cmsannotation type="cmsannotation" annotationid="Indegene IPO listing date" comment="subhead" text="Indegene IPO listing date">Indegene IPO listing date</cmsannotation> The shares of Indegene will be listed on the stock exchanges on May 13. SEE ALSO: <a href="https://www.businessinsider.in/stock-market/webstories/tbo-tek-ipo-company-details-to-risk-factors-all-you-need-to-know/slidelist/109946929.cms">TBO Tek IPO – Company details to risk factors, all you need to know</a> <a href="https://www.businessinsider.in/tech/mobile/news/google-has-silently-launched-the-pixel-8a-in-india-starting-at-52999/articleshow/109937286.cms">Google has quietly launched the Pixel 8a in India starting at ₹52,999</a> <a href="https://www.businessinsider.in/tech/apps/news/google-wallet-launched-in-india-store-your-loyalty-cards-boarding-passes-and-more/articleshow/109941139.cms">Google Wallet launched in India – store your loyalty cards, boarding passes and more</a>

Indegene IPO allotment – How to check allotment, GMP, listing date and more

<ul><li>Windlas Biotech is likely to announce its share allotment status on August 11.</li><li>The company provides pharmaceutical development services and large-scale manufacturing services.</li><li>The IPO of the company was subscribed 22.56 times on the last day of bidding.</li></ul>Windlas Biotech is likely to announce the allotment status of its initial public offering (IPO) on August 11. The IPO was open for subscription from August 4 to August 6 with a price band of ₹448-460. The company is looking to raise ₹402 crore on its upper price band. The company is a pharmaceutical formulations contract development and manufacturing organisation (CDMO). It provides pharmaceutical development services and large-scale manufacturing services. The IPO has received a good response from qualified institutional buyers and retail investors. The portion reserved for qualified institutional investors was subscribed 24.1 times while that for retail investors was subscribed 24.54 times. Here is how to <keyword id="11833554" type="UNKNOWN" weightage="20" keywordseo="windlas-biotech-ipo-allotment">Windlas Biotech IPO allotment</keyword> status on stock exchange website: <ul><li>Go to the <a href="https://www.bseindia.com/investors/appli_check.aspx">BSE website</a> or NSE website<a href="https://www1.nseindia.com/products/dynaContent/equities/ipos/ipo_login.jsp"> here</a>.</li><li>On BSE, Select 'Equity' and then from the dropdown, select 'Windlas Biotech’.</li><li>Now, enter your application number and PAN.</li><li>Click on 'Search'.</li><li>Please note the details will only be available once the shares are allotted.</li></ul>You can also visit the registrar website (Link Intime India) to check your application status. <ul><li>Visit the registrar's website <a href="https://linkintime.co.in/MIPO/Ipoallotment.html">here</a>.</li><li>Click on 'Select company' and click on 'Windlas Biotech’.</li><li>Once the company is selected, you will have to enter either your PAN detail, the application number, or the client ID.</li><li>Enter the captcha and click ’submit’. </li></ul>Once you hit 'submit', the status of your application will appear on the screen. Please ensure the details that you provide are correct. It will show the number of shares you subscribed to and the number of shares allotted to you. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/cryptocurrency/news/crypto-firm-mudrex-which-offers-mutual-fund-like-crypto-investment-tools-raises-2-5-million-in-a-seed-round/articleshow/85205115.cms">This Indian crypto company just raised $2.5 million to launch crypto mutual funds and ETFs</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/news/mukesh-ambanis-reliance-industries-may-bid-for-deutsche-telekom-ags-netherlands-subsidiary-reports-bloomberg/articleshow/85212874.cms">Mukesh Ambani's Reliance Industries may bid for Deutsche Telekom AG's Netherlands subsidiary, reports Bloomberg</a>

Here’s how to check Windlas Biotech IPO allotment status, listing date and more

<ul><li><keyword id="10967369" type="UNKNOWN" weightage="20" keywordseo="Rolex-Rings-IPO">Rolex Rings IPO</keyword> opened on July 28 and Friday, July 30 is the last day of its initial public offering (IPO) subscription.</li><li>So far, in the last two days of issue, it has received good response from retail investors and very tepid response from qualified institutional buyers (QIB).</li><li>The company looks to raise ₹731 crore with a price band of ₹880-900.</li></ul>If you are looking to invest in the initial public offering (IPO) of Rolex Rings, then go ahead as today (July 30) is the last day of the issue. The IPO application is live from 10 a.m. to 5 p.m. So far, in the first two days of subscription, the IPO has received good response from retail investors. However, it saw a tepid response from qualified institutional buyers (QIB). The portion reserved for retail investors was subscribed 14.09 times the issue size on the second day of the issue i.e., July 29 as of 4 p.m. Overall, the issue was subscribed 8.16 times on the second day. The IPO has received bids for 4.6 crore equity shares against the IPO size of 56.85 lakh equity shares. The IPO for Rolex Rings opened Wednesday, July 28 and will close on July 30 with a price band of ₹880-900. Further, most analysts have recommended subscribing to the IPO on good outlook for the automotive industry. <table style="border-width: initial; border-style: none;"></colgroup><tbody><tr><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">Broking house </td><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">Recommendation </td></tr><tr><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">Ventura </td><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr><tr><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">Nirmal Bang </td><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr><tr><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">ICICI Direct </td><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr><tr><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">Angel Broking </td><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">Neutral </td></tr><tr><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">Reliance Securities </td><td style="border-left:solid #000000 0.8333325pt;border-right:solid #000000 0.8333325pt;border-bottom:solid #000000 0.8333325pt;border-top:solid #000000 0.8333325pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr></tbody></table> “We observe that the company’s financial metrics as well as valuations are broadly in line with that of other players. The historical growth is lagging others, which is compensated by the company’s higher return ratios. Considering these metrics, we recommend subscribing to the issue from a long term perspective, “ said a report by Nirmal bang Securities. Analysts at Ventura Securities see an upside of 31% from the offer price of ₹900 over a period of 18-24 months. “Our target price of ₹1,177 (15 times FY24 earnings) represents a potential upside of 31% from the offer price of ₹900 over a period of 18-24 months. Better than expected recovery in the global economy, a rebound of the domestic automotive industry and the management’s guidance on higher capacity utilisation in the coming years bolster our confidence in improving revenue growth and profitability,” added the report. On the other hand, analysts at Angel Broking said that while valuations of the company are capturing all positives, promoter picking up 25 lakh shares in the company at ₹10 per share before the IPO is a concern. The company recently issued shares over 25 lakh to promoters at Rs 10 each on July 16 through optionally convertible redeemable preference shares (OCRPS), while it has set a price band of Rs 880-900 per share. “This way promoters received 7.29% stake in the company for ₹2.3 crore weeks ahead of the IPO,” said a <a href="https://www.bloombergquint.com/ipos/rolex-rings-sets-ipo-price-at-rs-880-900-it-issued-shares-to-promoters-at-rs-10">report</a>. SEE ALSO <a href="https://www.businessinsider.in/stock-market/news/windlas-biotech-to-raise-395-402-crore-through-public-listing-price-band-fixed-at-448-460/articleshow/84854594.cms">Windlas Biotech to raise ₹395-402 crore through public listing, price band fixed at ₹448-460</a> <a href="https://www.businessinsider.in/tech/mobile/news/googles-sundar-pichai-has-teased-the-whitechapel-chipset/articleshow/84853916.cms">Google teases Whitechapel chipset that may power Google Pixel 6 devices</a>

Today is the last day of Rolex Rings’ ₹731 crore IPO with a price band of ₹880-900

<ul><li>The finalisation of the allotment of <keyword id="2614989" type="PERSON" weightage="20" keywordseo="Aptus-Value-Housing-Finance">Aptus Value Housing Finance</keyword>’s public issue will be done on August 18.</li><li>Aptus Housing Finance was subscribed 17.20 times on the last day of bidding.</li><li>The <keyword id="11867411" type="UNKNOWN" weightage="20" keywordseo="retail-focused-housing-finance-company">retail-focused housing finance company</keyword> is looking to raise ₹2,780 crore from the primary market.</li></ul>The finalisation of the allotment of Aptus Value Housing Finance’s public issue will be done on August 18 and initiation of refunds will be initiated on August 20. Transfer of shares to the demat account will be done on August 23. The listing date is likely to be August 24. The <keyword id="35216" type="ENTERTAINMENT" weightage="20" keywordseo="initial-public-offering">initial public offering</keyword> (IPO) for Aptus Value Housing Finance ended on August 12. Aptus Housing Finance was subscribed 17.20 times on the last day of bidding. It received bids for 94.82 crore as against 5.51 crore offered by the company. The retail-focused housing finance company is looking to raise ₹2,780 crore from the primary market. The <keyword id="8894240" type="UNKNOWN" weightage="20" keywordseo="allotment-status">allotment status</keyword> of Aptus Value Housing Finance can be checked on <keyword id="35140" type="CITY" weightage="20" keywordseo="BSE">BSE</keyword> website and <keyword id="11867409" type="UNKNOWN" weightage="20" keywordseo="registrar-kfin-technologies-private-limited">registrar KFin Technologies Private Limited</keyword>. <cmsannotation type="cmsannotation" annotationid="How to check allotment status on the BSE website?" comment="subhead" text="How to check allotment status on the BSE website?">How to check allotment status on the BSE website?</cmsannotation> <ol><li>Open the<a href="https://www.bseindia.com/"> BSE </a>website on any smart device.</li><li>On the website, enter the issue name on the right side and select ‘Equity’ from the drop down list.</li><li>Enter your application number and Permanent Account Number (<keyword id="61610" type="ORGANIZATION" weightage="20" keywordseo="pan">PAN</keyword>).</li><li>Select the box saying ‘Am not a Robot’ and click on the Search option.</li><li>After clicking on search, your IPO status will become available.</li></ol> <cmsannotation type="cmsannotation" annotationid="How to check allotment on the KFin website?" comment="subhead" text="How to check allotment on the KFin website?">How to check allotment on the <keyword id="11867408" type="UNKNOWN" weightage="20" keywordseo="kfin">KFin</keyword> website?</cmsannotation> <ol><li>Open the <a href="https://ris.kfintech.com/ipostatus/ipos.aspx">KFin</a> website on any smart device.</li><li>There will be 5 links to check IPO Allotment, click on any one of them. </li><li>Select the IPO from the drop down menu and then select application number/ DPID/Client ID/PAN. Note: The IPO name will be visible on the finalisation date i.e August 18.</li><li>Then enter your application number and the above number visible on your screen (CAPTCHA).</li><li>Now click at the ‘Submit’ option and your IPO Allotment status will be displayed on your screen.</li></ol> Make sure you enter your details correctly. It will display the number of shares you subscribed and number of shares allotted to you. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/chemplast-sanmar-ipo-how-to-check-allotment-date-and-status-listing-date-and-more/articleshow/85362052.cms">Chemplast Sanmar IPO: Here’s how to check allotment status, listing date and more</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/windlas-biotech-ipo-makes-a-weak-stock-market-debut-list-at-4-5-discount-on-exchanges/articleshow/85361052.cms">Windlas Biotech IPO makes a weak stock market debut; list at 4.5% discount on exchanges</a>

Aptus Value Housing Finance IPO: Check allotment status, listing date and more

<ul><li><keyword id="3519758" type="PERSON" weightage="20" keywordseo="route-mobile">Route Mobile</keyword> made a strong debut on the bourses on Monday, surging 105% over its initial public offer (IPO) price.</li><li>Route Mobile issued the IPO at a price band of ₹350, but it listed at ₹717 apiece. </li><li>Route Mobile’s total market cap rose to ₹3,980 crore at 10:05 am.</li></ul>The cloud communication platform services provider, Route Mobile, made a strong debut on the bourses on Monday, surging 105% over its initial public offer (IPO) price. The company had garnered a stellar response from investors in its ₹600-crore IPO, which closed on September 11 with a whopping oversubscription of 73.30 times. Investors who applied for the IPO are being rewarded with hefty gains. Route Mobile issued the IPO at a price band of ₹350, but it listed at ₹717 apiece, with an upside of 105%. <table style="border-width: initial; border-style: none;"></colgroup><tbody><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Top IPOs this year </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Listing gains </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Happiest Minds Technologies Ltd </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">138% </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Rossari Biotech Ltd </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">65% </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">SBI Cards and Payment Services Ltd </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-12% </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Mindspace Business Parks </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">10.55% </td></tr></tbody></table> However, the weakness in the market weighed on the shares and it was trading 9% lower at ₹646 a piece at 10:12 am. <div type="image" title="Route Mobile" msid="78227918" hostid="261"></div> Route Mobile’s total market cap rose to ₹3,980 crore at 10:05 am. A total traded quantity of 10.31 lakh shares changed hands on BSE amounting to a turnover of ₹73.76 crore. The company will trade with the symbol of ‘ROUTE’ on the Indian stock exchanges. The bumper listing was already on the cards! After a strong debut of Happiest Minds Tech last week, Route Mobile was already expected to witness stellar listing. Its monopoly in the sector is something that makes the company stand out in the IPO rush. Ahead of its IPO, the company had already raised ₹180 crore from 15 anchor investors, including Goldman Sachs, Franklin Templeton Mutual Fund, and SBI Life Insurance, Kuwait Investment Authority, Vantage Equity Fund, and SBI Life Insurance, among others. SEE ALSO: <a href="https://www.businessinsider.in/business/telecom/news/airtel-seems-to-be-sticking-to-its-strengths-while-its-shareholders-want-jio-like-fireworks/articleshow/78222570.cms" data-type="tilCustomLink">Airtel seems to be sticking to its strengths while its shareholders want Jio-like fireworks</a> <a href="https://www.businessinsider.in/stock-market/news/top-stocks-to-watch-future-group-stocks-irctc-rites-sbi-bank-of-india-pnb-and-more/articleshow/78226309.cms" data-type="tilCustomLink">Top stocks to watch— Future Group stocks, IRCTC, RITES, SBI, Bank of India, PNB and more</a>

After Happiest Minds Tech, Route Mobile doubles the money invested in the IPO

Watch out for 4 IPOs opening on August 4— here’s a snapshot for each of the companies selling shares tomorrow

Health Minister Dr. Harsh Vardhan along with his wife Nutan Goel received their first Covid vaccine doses on Tuesday in the Delhi Heart and Lung Institute. Vardhan and Goel received <keyword id="149108" type="COMPANY" weightage="20" keywordseo="Bharat-Biotech">Bharat Biotech</keyword>'s Covaxin and paid ₹250 each for the doses. After receiving the vaccine he appealed that those who can afford the cost of vaccination must go to their nearest private facility to get vaccinated. He also spoke of vaccine appropriate behaviour where people must adhere to getting vaccinated and help defeat the pandemic. "After Covid appropriate behaviour, we need to affirm to vaccine appropriate behaviour. We all should come forward and help the society from allaying the menace of <keyword id="8763838" type="UNKNOWN" weightage="20" keywordseo="covid-19">Covid-19</keyword>," he said. "Vaccine would not just save you from the disease but also your closed ones," Vardhan added. Vardhan also said that the percentage of post-vaccination effects are just 0.00004 of the total vaccination and one should not be afraid of the minor ones that come depending upon age. Meanwhile, he also thanked those who got in the queue of registration on the first day of phase three Covid vaccination. "The response was overwhelming and it shows our resolve to defeat the pandemic. I appeal every eligible beneficiary to come forward for the vaccination," he added. Vaccines are being provided free of charge at the government health facilities and on a payment basis in the private health facilities. All private <keyword id="6365858" type="UNKNOWN" weightage="20" keywordseo="hospitals">hospitals</keyword> can charge Rs 150 for vaccines and Rs 100 for service charges fixed by the Central government. Around 10,000 hospitals empanelled under the Ayushman Bharat-PMJAY and 687 hospitals under CGHS can be used by states as Covid Vaccination Centres (CVCs). The phase three of Covid vaccination covering 27 crore of population aged above 60 and those above 45 with comorbidities started from Monday. The previous two phases were started with vaccination of around three crore of healthcare and frontline workers in India. SEE ALSO: <a href="https://www.businessinsider.in/india/news/new-electricity-late-payment-surcharge-rules-announced-but-consumer-electricity-bills-may-not-decrease/articleshow/81286847.cms">New electricity late payment surcharge rules announced – but consumer electricity bills may not decrease</a> <a href="https://www.businessinsider.in/stock-market/news/how-to-check-allotment-status-of-heranba-industries-ipo/articleshow/81286739.cms">Heranba Industries IPO: Here is how to check share allotment status</a> <a href="https://www.businessinsider.in/thelife/personalities/news/meet-jay-chaudhry-the-man-who-studied-under-a-tree-in-himachal-to-become-one-of-the-worlds-top-billionaires-today/articleshow/81288884.cms">Meet Jay Chaudhry, the man who studied under a tree in Himachal to become one of the world’s top billionaires today</a>

'Those who can afford should get vaccinated in private hospitals' says Health Minister

New Delhi, <keyword id="149108" type="COMPANY" weightage="20" keywordseo="Bharat-Biotech">Bharat Biotech</keyword> has claimed that amongst all the <keyword id="24209" type="PERSON" weightage="20" keywordseo="vaccine">vaccine</keyword> platforms such as an mRNA-based vaccine, DNA-based vaccine, vector-based vaccine, or live attenuated vaccines, etc., the inactivated vaccines being developed by it for Covid 19 are safest, and hence, the adverse reactions are lesser. In a series of frequently asked questions (FAQs) for its trials, Bharat Biotech said BBV-152 is a whole-virion inactivated SARS-CoV-2 vaccine. Amongst all the vaccine platforms such as an mRNA-based vaccine, DNA-based vaccine, vector-based vaccine, or live attenuated vaccines, etc., the inactivated vaccines are safest, and hence, the adverse reactions are lesser. It said about 755 <keyword id="9696" type="PERSON" weightage="20" keywordseo="Participants">participants</keyword> have been vaccinated in phase 1 &amp; 2 clinical trials. No <keyword id="2304765" type="PERSON" weightage="20" keywordseo="Serious-Adverse-Events">serious adverse events</keyword> have been reported to be related to the vaccine in phase 1 and 2 clinical trials. It said vaccination with BBV-152B may protect the participants only after 14-days post-second dose of vaccination. Hence, the participants should follow the below precautions to avoid <keyword id="10467734" type="UNKNOWN" weightage="20" keywordseo="sarscov-2-infection">SARSCoV-2 infection</keyword> up to 14-days post-second dose of vaccination. Since the participants are vaccinated before the results of the RT-PCR and the ELISA tests are known, there is a chance that the participants with asymptomatic SARS-CoV-2 infection may enter the study, and later show <keyword id="8889783" type="UNKNOWN" weightage="20" keywordseo="Covid-19-symptoms">Covid-19 symptoms</keyword>. Also, the participants who are very recently infected with SARS-CoV-2just before the first dose of vaccination, and have viral loads below the limit of detection (LoD) of the <keyword id="3652596" type="COMPANY" weightage="20" keywordseo="RTPCR">RTPCR</keyword> test kit, may not be detected by RT-PCR, and later show the Covid-19 symptoms. Since there is also an equal chance of getting a placebo for every participant, 50% of the participant will get the placebo, and they may get SARS-CoV-2 infection/Covid-19 any time after vaccination. Bharat Biotech said in the event of successful evidence of efficacy detected during the interim analysis, participants who received placebo may be provided with vaccination at the end of the study, after getting due approval from the regulatory authorities. It said that whenever a vaccine get approval first Health care workers, Front line workers will receive vaccine. It will take at least 6 months for elderly (more than 65 years to receive the vaccine). It will take a minimum of 6-12 months for a person under the ages of 60 to receive a vaccine, due to limited supply. "If you participate in this trial, this vaccine will most likely get licensed within a few months. And if you received a placebo, we will contact you and give you the vaccine, thus giving you priority access to the vaccine (even if you are below 60 years)," it said. SEE ALSO: <a href="https://www.businessinsider.in/business/news/ikea-india-cfo-says-she-still-has-3500-crore-to-be-spent-in-india-the-pandemic-has-changed-targets-but-not-the-investment-plan/articleshow/79790938.cms">INTERVIEW: Ikea CFO says she still has ₹3,500 crore to be spent in India⁠— the pandemic has changed targets but not the investment plan</a> <a href="https://www.businessinsider.in/science/health/news/india-will-produce-300-million-doses-of-the-russian-sputnik-v-covid-19-vaccine-next-year/articleshow/79795341.cms">India will produce 300 million doses of the Russian Sputnik V COVID-19 vaccine next year</a> <a href="https://www.businessinsider.in/stock-market/news/how-to-check-mrs-bectors-food-specialities-ipo-allotment-status-online/articleshow/79808672.cms">Mrs Bectors Food Specialities IPO allotment: Here’s how to check share allotment status</a>

Inactivated vaccines are safest with lesser adverse reactions: Bharat Biotech

Hyderabad, <keyword id="149108" type="COMPANY" weightage="20" keywordseo="Bharat-Biotech">Bharat Biotech</keyword> on Tuesday announced successful recruitment of 13,000 volunteers, and continued progress towards achieving the goal of 26,000 participants for Phase III <keyword id="122283" type="PERSON" weightage="20" keywordseo="Clinical-trial">clinical trial</keyword> of its <keyword id="9594299" type="UNKNOWN" weightage="20" keywordseo="coronavirus-vaccine-covaxin">coronavirus vaccine Covaxin</keyword> across <keyword id="10475645" type="UNKNOWN" weightage="20" keywordseo="multiple-sites">multiple sites</keyword> in India. The Phase III human clinical trials of Covaxin began mid-November, targeted to be done in 26,000 volunteers across India. Suchitra Ella, Joint Managing Director of Bharat Biotech termed this as an unprecedented vaccine trial ever in India. She said they were overwhelmed with the steady rise in participation. "We sincerely thank all the 13,000 volunteers across the country for their support in enabling us to bring out a safe and efficacious Indian vaccine for <keyword id="8763838" type="UNKNOWN" weightage="20" keywordseo="covid-19">COVID-19</keyword>. This pro-vaccine public health volunteerism is a morale booster for us to achieve our milestone target of 26,000 soon." This is India's first and only Phase III efficacy study for a COVID-19 vaccine, and the largest phase III efficacy trial ever conducted for any vaccine in India. Covaxin has been evaluated in approximately 1,000 subjects in Phase I and Phase II clinical trials, with promising safety and immunogenicity results, with acceptance in international peer reviewed scientific journals, the Hyderabad-based company said. Covaxin, India's indigenous Covid-19 vaccine by Bharat Biotech is developed in collaboration with <keyword id="1256547" type="COMPANY" weightage="20" keywordseo="The-Indian-Council-of-Medical-Research">the Indian Council of Medical Research</keyword> (ICMR) -- National Institute of Virology (NIV). This indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) bio-containment facility, one of its kind in the world. Covaxin is a highly purified and inactivated 2 dose SARS-CoV2 vaccine, manufactured in a Vero cell manufacturing platform with an excellent safety track record of more than 300 million doses. SEE ALSO: <a href="https://www.businessinsider.in/stock-market/news/top-stocks-to-watch-spicejet-interglobe-aviation-tata-motors-pfizer-asian-paints-niit-lupin-and-others/articleshow/79849749.cms">Top stocks to watch – SpiceJet, InterGlobe Aviation, Tata Motors, Pfizer, Asian Paints, NIIT, Lupin, and others</a> <a href="https://www.businessinsider.in/stock-market/news/how-to-check-mrs-bectors-food-specialities-ipo-allotment-status-online/articleshow/79808672.cms?upcache=2">Mrs Bectors Food Specialities IPO allotment today: Here’s how to check share allotment status</a> <a href="https://www.businessinsider.in/stock-market/news/cryptocurrency-exchange-coindcx-raises-13-9-million-funding/articleshow/79850829.cms">Cryptocurrency exchange CoinDCX has raised $20 million since the pandemic broke out⁠ — the founder says he is hiring aggressively as volumes have tripled</a>

Covaxin vaccine update: Bharat Biotech brings on board 13,000 volunteers for Phase III trials across multiple sites in India

<ul><li>The stock fell steeply from its issue price on market debut.</li><li>Its market cap is ₹2,111 crore, as per Bombay Stock Exchange.</li><li>The ₹775 crore IPO was subscribed 1.6 times the shares on offer. </li></ul><keyword id="624860" type="General" weightage="20" keywordseo="yatra-online" source="Orion">Yatra Online</keyword>’s stock saw a volatile market debut on Thursday. Its price slipped over 8% early on as trading started but the fall was later stemmed to 5% as of 10:10 am. The stock gained during the session but the listing loss over its IPO price remained at 4%, at its closing price of ₹135. Its issue price is at ₹142, which is the upper end of the price band. The stock is one of the rare few to see negative listing gains during this very busy IPO season. Its market cap is ₹2,111 crore, as per Bombay Stock Exchange. Here are the listing gains of the last few market debuts <table style="border-width: initial; border-style: none;" class="redcator-table-advance"></colgroup><tbody><tr><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Company </td><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Listing gains </td></tr><tr><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Signature Global </td><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">18% </td></tr><tr><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Sai Silks Kalamandir </td><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">10% </td></tr><tr><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">EMS Ltd </td><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">32.58% </td></tr><tr><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">R R Kabel </td><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">15.6% </td></tr><tr><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Jupiter Life Line Hospitals </td><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">46% </td></tr><tr><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Rishabh Instruments </td><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">0.18% </td></tr><tr><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Ratnaveer Precision Engineering </td><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">37% </td></tr><tr><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Vishnu Prakash R Punglia </td><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">47% </td></tr><tr><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Aeroflex </td><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">83% </td></tr><tr><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Pyramid Technoplast </td><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">12% </td></tr><tr><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">TVS Supply Chain </td><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">5% </td></tr><tr><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">SBFC </td><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">43% </td></tr><tr><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Concord Biotech </td><td style="border-left:solid #000000 0.9999974999999999pt;border-right:solid #000000 0.9999974999999999pt;border-bottom:solid #000000 0.9999974999999999pt;border-top:solid #000000 0.9999974999999999pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">21% </td></tr></tbody><tbody></tbody></table> The ₹775 crore initial public offer was subscribed 1.6 times the shares on offer, on the last day of the subscription. Qualified institutional buyer (QIB) and retail portions were subscribed twice over, while non-institutional investor portion was not fully subscribed. The price band of the issue has been fixed at ₹135-142 per equity share. The IPO comprised a fresh issuance of shares worth ₹602 crore and an offer for sale (OFS) of up to 12,183,099 shares. It had undertaken a pre-IPO placement of ₹62.01 crore by way of rights issue and allotted 2,627,697 shares of face value ₹1 each to its promoter, THCL in December 2022. ‘Can gain from industry tailwinds’ Yatra Online offers access to hotels, homestays, and other accommodations through its platform. It is a one-stop shop for travellers, offering vacation packages as well as visa facilitation, tours, sightseeing, shows, and events. Proceeds from the fresh issue will be utilised towards strategic investments, acquisitions, and inorganic growth, customer acquisition and retention, technology, and other organic growth initiatives and general corporate purposes. The company claims to be India’s largest corporate travel services provider in terms of number of corporate clients. It is the third largest online travel company in India among key online travel agency (OTA) players in terms of gross booking revenue and operating revenue for FY23. The company’s revenues have been growing steadily for the last three years and has turned profitable in FY23, after cutting its losses progressively over two years. At the upper price band, the company is valued at a market-cap to sales ratio of 5.8 times as per its FY23 earnings. Its peer EaseMyTrip is valued at 15.7 times, as per Anand Rathi Securities. “We believe that for Yatra there is a scope of business improvement on the back of industry tailwinds, brand recall and business scalability, resulting in expansion of the EBITDA margin from here on,” the report said, adding that it recommends a ‘subscribe’ rating for the long term.

Yatra Online stock slips below its issue price on listing

<keyword id="92247" type="COMPANY" weightage="20" keywordseo="Johnson-Johnson">Johnson &amp; Johnson</keyword>'s <keyword id="11735066" type="UNKNOWN" weightage="20" keywordseo="single-dose">single-dose</keyword> COVID-19 vaccine has been given Emergency Use approval in <keyword id="3658" type="COUNTRY" weightage="20" keywordseo="India">India</keyword>, <keyword id="700200" type="ORGANIZATION" weightage="20" keywordseo="Union-Health">Union Health</keyword> minister Mansukh Mandaviya said on Saturday. He said this will further boost the country's collective fight against the novel coronavirus infection. "India expands its vaccine basket! Johnson and Johnson's single-dose COVID-19 vaccine is given approval for Emergency Use in India. Now India has five <keyword id="2503801" type="ORGANIZATION" weightage="20" keywordseo="EUA">EUA</keyword> vaccines. This will further boost our nation's collective fight against #COVID19," the minister tweeted. The US-based pharmaceutical company had applied for <keyword id="9408526" type="UNKNOWN" weightage="20" keywordseo="emergency-use-authorisation">Emergency Use Authorisation</keyword> for its jab on Friday and was granted the approval the same day by the Drugs Controller General of India (DCGI). The five vaccines granted Emergency Use Authorisation in India are Serum Institute's Covishield, Bharat Biotech's Covaxin, Russia's Sputnik V, Moderna and now Johnson &amp; Johnson. SEE ALSO <a href="https://www.businessinsider.in/tech/news/google-is-now-using-chrome-as-another-security-layer-for-account-sign-ins/articleshow/84975356.cms">Google is now using Chrome as an added security layer for account sign-ins</a> <a href="https://www.businessinsider.in/stock-market/news/how-to-check-allotment-status-of-glenmark-life-sciences-ipo/articleshow/84978486.cms">Glenmark Life Sciences IPO: How to check allotment status, listing date and more</a>

India now has a fifth vaccine. Johnson & Johnson's single-dose COVID-19 shot gets government nod.

New Delhi, In a major development, India on Saturday recorded 25,152 new coronavirus cases and 347 deaths, taking the total number of infected people since January past the one crore-mark, according to <keyword id="4585792" type="COMPANY" weightage="20" keywordseo="the-ministry-of-health-and-family-welfare">the Ministry of Health and Family Welfare</keyword>'s data. The country crossed the grim milestone almost eleven months after the first case was reported on January 30 in Thrissur district of Kerala. Since then, the country has recorded 10,004,599 coronavirus cases and 14,51,36 deaths. The number of infections had crossed the 1 million-mark on July 17; 2 million on August 7; 3 million on August 23; 4 million on September 5; 5 million on September 16; 6 million on September 28; 7 million on October 11; 8 million on October 29; and 90 lakh on November 20. While it took over five months to touch 1 million, it amassed 6 million with August and October. India has been recording the second-highest numbers of coronavirus cases in the world since August this year, following the US, which had crossed the milestone of one crore infections on November 9. India also fought through a massive wave of infection in September when the pandemic peaked and recorded a highest single-day spike of 97,894 cases on September 16. Number of cases have drastically come down since. Notably the recovery rate is 95.46%, while the death rate is 1.45%. The <keyword id="9281338" type="UNKNOWN" weightage="20" keywordseo="active-caseload">active caseload</keyword> is also below four lakh for the last 12 days. India is one of the top countries with the highest recovery rate globally. According to <keyword id="3284300" type="COMPANY" weightage="20" keywordseo="The-Health-Ministry">the Health Ministry</keyword>, the chasm between active cases and recovered cases is continuously widening. As many as 95,50,712 people have recovered while 3,08,751 remain currently active. A total of 16,00,90,514 samples have been tested for <keyword id="8763838" type="UNKNOWN" weightage="20" keywordseo="covid-19">Covid-19</keyword> till date. Of these, 11,71,868 samples were tested on Friday, <keyword id="1256547" type="COMPANY" weightage="20" keywordseo="The-Indian-Council-of-Medical-Research">the Indian Council of Medical Research</keyword> (ICMR) said. Maharashtra continues to be the worst-hit state with 18,88,767 cases till date. Over 76% of the daily new cases are being reported by 10 states and union territory and in the random order they include -- Kerala, West Bengal, Chhattisgarh, Uttar Pradesh, Delhi, Tamil Nadu, Madhya Pradesh, Rajasthan and Gujarat. Over 75% of the deaths are being reported from Maharashtra, West Bengal, Delhi, Kerala, Uttar Pradesh, Haryana, Punjab, Tamil Nadu, Rajasthan and Chhattisgarh. There is, however, light at the end of the tunnel as India has eight Covid-19 vaccine candidates, including three indigenous vaccines, under different stages of clinical trials which could be ready for authorization in near future. It includes AstraZeneca and Oxford university developed and Serum Institute of India manufactured Covishield; Covaxin by Bharat Biotech Limited; ZyCoV-D by Zydus Cadila and Russian vaccine candidate Sputnik-V. The list also contains NVX-CoV2373 by SII, HGCO19 by Geneva, and two unlabeled vaccines -- Recombinant Protein Antigen-based vaccine by Biological E Limited and Inactivated rabies vector platform by Bharat Biotech. The central government plans to vaccinate nearly 30 crore people during the first phase of vaccination. It will be offered to one crore healthcare workers along with 2 crore frontline and essential workers and 27 crore elderly, mostly above the age of 50 years with comorbidities such as diabetes, heart or liver ailments. SEE ALSO: <a href="https://www.businessinsider.in/stock-market/news/how-to-check-mrs-bectors-food-specialities-ipo-allotment-status-online/articleshow/79808672.cms">Mrs Bectors Food Specialities IPO allotment: Here’s how to check share allotment status</a> <a href="https://www.businessinsider.in/business/news/ikea-india-cfo-says-she-still-has-3500-crore-to-be-spent-in-india-the-pandemic-has-changed-targets-but-not-the-investment-plan/articleshow/79790938.cms">INTERVIEW: Ikea CFO says she still has ₹3,500 crore to be spent in India⁠— the pandemic has changed targets but not the investment plan</a> <a href="https://www.businessinsider.in/science/health/news/india-will-produce-300-million-doses-of-the-russian-sputnik-v-covid-19-vaccine-next-year/articleshow/79795341.cms">India will produce 300 million doses of the Russian Sputnik V COVID-19 vaccine next year</a>

You Searched For "concord biotech ipo allotment status" and got 13 results

Concord Biotech IPO allotment – how to check allotment, GMP, listing date and more

Sourabh Jain

Indegene IPO allotment – How to check allotment, GMP, listing date and more

Sourabh Jain

Here’s how to check Windlas Biotech IPO allotment status, listing date and more

Bhakti Makwana

Today is the last day of Rolex Rings’ ₹731 crore IPO with a price band of ₹880-900

Bhakti Makwana

Aptus Value Housing Finance IPO: Check allotment status, listing date and more

Vaamanaa Sethi

After Happiest Minds Tech, Route Mobile doubles the money invested in the IPO

Navdeep Yadav

Watch out for 4 IPOs opening on August 4— here’s a snapshot for each of the companies selling shares tomorrow

Bhakti Makwana

'Those who can afford should get vaccinated in private hospitals' says Health Minister

IANS

Inactivated vaccines are safest with lesser adverse reactions: Bharat Biotech

IANS

Covaxin vaccine update: Bharat Biotech brings on board 13,000 volunteers for Phase III trials across multiple sites in India

IANS

Yatra Online stock slips below its issue price on listing

Katya Naidu

India now has a fifth vaccine. Johnson & Johnson's single-dose COVID-19 shot gets government nod.

PTI

India's COVID-19 caseload surpasses one crore-mark with 25,152 fresh cases

IANS

Popular Keywords

Buying Guides